Patent Licensing Deals Could Be More Costly Under FTC Proposed Rules
Executive Summary
Federal Trade Commission is proposing to amend pre-merger notification rules related to the transfer of exclusive patent rights in the pharmaceutical industry; the change would require reporting transactions in which the licensor retains exclusive manufacturing rights.
You may also be interested in...
Exclusive Drug Patent Licensing Deals Face New Scrutiny By FTC/DOJ
The Federal Trade Commission finalized a proposed rule that requires pharma companies to report certain transactions transferring exclusive patent rights; PhRMA says annual costs will go far beyond FTC’s $1.2 million estimate.
Reverse Payment Settlements Suffer Reversal Of Fortune At Third Circuit
FTC ends its losing streak on patent settlement suits as the Third Circuit says “rule of reason” rather than “scope of patent” analysis should be applied to brand/generic settlements; appeals court reinstates suit by direct purchasers challenging Schering’s payments to Upsher-Smith and ESI Lederle.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.